Literature DB >> 16549764

Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

J Steven Jacobsen1, Chi-Cheng Wu, Jeffrey M Redwine, Thomas A Comery, Robert Arias, Mark Bowlby, Robert Martone, John H Morrison, Menelas N Pangalos, Peter H Reinhart, Floyd E Bloom.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which numerous mouse models have been generated. In both AD patients and mouse models, there is increasing evidence that neuronal dysfunction occurs before the accumulation of beta-amyloid (Abeta)-containing plaques and neurodegeneration. Characterization of the timing and nature of preplaque dysfunction is important for understanding the progression of this disease and to identify pathways and molecular targets for therapeutic intervention. Hence, we have examined the progression of dysfunction at the morphological, functional, and behavioral levels in the Tg2576 mouse model of AD. Our data show that decreased dendritic spine density, impaired long-term potentiation (LTP), and behavioral deficits occurred months before plaque deposition, which was first detectable at 18 months of age. We detected a decrease in spine density in the outer molecular layer of the dentate gyrus (DG) beginning as early as 4 months of age. Furthermore, by 5 months, there was a decline in LTP in the DG after perforant path stimulation and impairment in contextual fear conditioning. Moreover, an increase in the Abeta42/Abeta40 ratio was first observed at these early ages. However, total amyloid levels did not significantly increase until approximately 18 months of age, at which time significant increases in reactive astrocytes and microglia could be observed. Overall, these data show that the perforant path input from the entorhinal cortex to the DG is compromised both structurally and functionally, and this pathology is manifested in memory defects long before significant plaque deposition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16549764      PMCID: PMC1405622          DOI: 10.1073/pnas.0600948103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

Review 2.  Dendritic spine pathology: cause or consequence of neurological disorders?

Authors:  John C Fiala; Josef Spacek; Kristen M Harris
Journal:  Brain Res Brain Res Rev       Date:  2002-06

3.  Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

Authors:  Hai-Wei Wang; Joseph F Pasternak; Helen Kuo; Helen Ristic; Mary P Lambert; Brett Chromy; Kirsten L Viola; William L Klein; W Blaine Stine; Grant A Krafft; Barbara L Trommer
Journal:  Brain Res       Date:  2002-01-11       Impact factor: 3.252

4.  The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Marcus A Westerman; Deirdre Cooper-Blacketer; Ami Mariash; Linda Kotilinek; Takeshi Kawarabayashi; Linda H Younkin; George A Carlson; Steven G Younkin; Karen H Ashe
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

5.  Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus.

Authors:  Qi-Sheng Chen; Wei-Zheng Wei; Takeshi Shimahara; Cui-Wei Xie
Journal:  Neurobiol Learn Mem       Date:  2002-05       Impact factor: 2.877

6.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

7.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models.

Authors:  A Y Hsia; E Masliah; L McConlogue; G Q Yu; G Tatsuno; K Hu; D Kholodenko; R C Malenka; R A Nicoll; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 8.  Learning and memory in transgenic mice modeling Alzheimer's disease.

Authors:  K H Ashe
Journal:  Learn Mem       Date:  2001 Nov-Dec       Impact factor: 2.460

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis.

Authors:  Jeffrey M Redwine; Barry Kosofsky; Russell E Jacobs; Dora Games; John F Reilly; John H Morrison; Warren G Young; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-24       Impact factor: 11.205

View more
  272 in total

1.  Pathway-specific alteration of synaptic plasticity in Tg2576 mice.

Authors:  Jung Hoon Jung; Kyongman An; Oh Bin Kwon; Hye-sun Kim; Joung-Hun Kim
Journal:  Mol Cells       Date:  2011-06-01       Impact factor: 5.034

2.  SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β protein oligomerization and memory loss in mouse model of Alzheimer disease.

Authors:  Kazuma Murakami; Nakaba Murata; Yoshihiro Noda; Shoichi Tahara; Takao Kaneko; Noriaki Kinoshita; Hiroyuki Hatsuta; Shigeo Murayama; Kevin J Barnham; Kazuhiro Irie; Takuji Shirasawa; Takahiko Shimizu
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

Review 3.  Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease.

Authors:  Peter Penzes; Jon-Eric Vanleeuwen
Journal:  Brain Res Rev       Date:  2011-01-26

Review 4.  Genetic animal models of cerebral vasculopathies.

Authors:  Jeong Hyun Lee; Brian J Bacskai; Cenk Ayata
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 5.  Synapses and Alzheimer's disease.

Authors:  Morgan Sheng; Bernardo L Sabatini; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-05-01       Impact factor: 10.005

Review 6.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

7.  A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease.

Authors:  Sara Landgren; Malin von Otter; Mona Seibt Palmér; Caroline Zetterström; Staffan Nilsson; Ingmar Skoog; Deborah R Gustafson; Lennart Minthon; Anders Wallin; Niels Andreasen; Nenad Bogdanovic; Jan Marcusson; Kaj Blennow; Henrik Zetterberg; Petronella Kettunen
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

8.  Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61.

Authors:  Pradeep Kurup; Yongfang Zhang; Jian Xu; Deepa V Venkitaramani; Vahram Haroutunian; Paul Greengard; Angus C Nairn; Paul J Lombroso
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

9.  Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease.

Authors:  A Parachikova; C W Cotman
Journal:  Neurobiol Dis       Date:  2007-07-10       Impact factor: 5.996

10.  Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model.

Authors:  Tara L Spires-Jones; Melanie Meyer-Luehmann; Jennifer D Osetek; Phillip B Jones; Edward A Stern; Brian J Bacskai; Bradley T Hyman
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.